News

Ranexa (ranolazine) was well tolerated in the study, named ERICA, and there were no cases of syncope (fainting). Under the trial’s special protocol assessment (SPA) process agreement, these

Results from the first treatment phase of the EPIC(3) trial, a major ongoing study, have shown that a significant portion of patients chronically infected with hepatitis C virus

A poster presentation at the 96th annual meeting of the American Association for Cancer Research (AACR) in California, reviewed the results of a study designed to explore the

The market share of Cialis in France has grown consistently since the product was introduced in Europe in February 2003. Since December 2004, Cialis has secured an additional

The monoclonal antibodies will be provided by Antibodies by Design and the complementary peptide-based services and products from JPT. Each partner will offer the services of the other

The study, published in the journal Molecular Cancer Therapeutics and funded by Mars Incorporated, explains how pentameric procyanidin (pentamer), a compound found in cocoa, deactivates a number of

The joint UK National health Service (NHS) Greater Glasgow and University of Glasgow project, Glasgow Biomedicine, is part of ‘Medicine in Glasgow’, a unique collaboration aiming to develop

In a presentation at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, California, it was reported that CR011 selectively binds to GPNMB,

In previously published studies, PT-100 (talabostat) was shown to elicit anti-tumor T-cell responses in mice with fully functioning immune systems. The recently announced results have advanced this work